Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity
Authors
Keywords
HDAC2, GBM, Temozolomide, MRP1, Sensitivity
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 78, Issue 6, Pages 1289-1296
Publisher
Springer Nature
Online
2016-11-10
DOI
10.1007/s00280-016-3188-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription
- (2016) Pingjiang Ye et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor – belinostat – in glioblastoma cell lines: a preliminary report
- (2016) Magdalena Kusaczuk et al. INVESTIGATIONAL NEW DRUGS
- HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy
- (2016) Haishan Zhao et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma
- (2016) Rikke D. Rasmussen et al. Molecular Oncology
- Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme
- (2015) Amanda Tivnan et al. Frontiers in Neuroscience
- Antitumor Effects in Hepatocarcinoma of Isoform-Selective Inhibition of HDAC2
- (2014) Yun-Han Lee et al. CANCER RESEARCH
- Histone deacetylase inhibitors and cell death
- (2014) Jing Zhang et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Radiosensitization of glioblastoma cells using a histone deacetylase inhibitor (SAHA) comparing carbon ions with X-rays
- (2014) Lara Barazzuol et al. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
- Involvement of activating ERK1/2 through G protein coupled receptor 30 and estrogen receptor α/β in low doses of bisphenol A promoting growth of Sertoli TM4 cells
- (2014) Li-Chen Ge et al. TOXICOLOGY LETTERS
- HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells
- (2013) Laurence Booth et al. CANCER BIOLOGY & THERAPY
- Molecular characterization leads the way
- (2013) Roger Stupp et al. Nature Reviews Clinical Oncology
- Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells
- (2012) Yong Tang et al. CANCER BIOLOGY & THERAPY
- Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers
- (2012) Günter Niegisch et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Role for Class I histone deacetylases in multidrug resistance
- (2011) Yichun Xu et al. EXPERIMENTAL CELL RESEARCH
- Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic
- (2011) Jacob E. Shabason et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Aberrant Regulation of HDAC2 Mediates Proliferation of Hepatocellular Carcinoma Cells by Deregulating Expression of G1/S Cell Cycle Proteins
- (2011) Ji Heon Noh et al. PLoS One
- HDAC expression and clinical prognosis in human malignancies
- (2008) Wilko Weichert CANCER LETTERS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now